Calliditas: Asahi Kasei to acquire CALTX

Asahi Kasei today announced a public cash offer to acquire all shares in Calliditas for SEK 208/share (+83% premium), representing a total value of SEK 11.164bn. The Offer will also include a concurrent offer to acquire all ADS for SEK 416/ADS (+74% premium). We believe that the offer fully recogni

Calliditas: despite weaker Q1 sales, patient enrolment is showing stea...

Tarpeyo Q1 2024 sales reached SEK278.3m (USD28m), representing a 20% decrease vs the previous quarter, primarily due to the cyberattack that Change Healthcare (part of the United Group) suffered in February 2024, which lead to disruptions in claim processing (approx. USD4.7m). As such, some of Q1 s

CALLIDITAS: Cautious guidance leaves room for surprise as Tarpeyo ente...

Yesterday, Calliditas reported its Q4 Tarpeyo sales reaching SEK 347.3m (USD 32.6m), with total net sales at SEK 1.206bn for FY 2023, in line with the USD 100-120m guidance, and a cash position at SEK 973.7m. All in all, the Q4 performance was solid, while the main surprise came with the conservati

Bryan, Garnier & Co Healthcare Daily | Calliditas

Reports Q1 2023 results, sees sales uptake by the end of the quarter

Q1 2023 Tarpeyo sales reached SEK 186m (USD 17m), representing a modest 11% increase vs. the previous quarter. The ambitious FY 2023 net sales guidance for Tarpeyo of USD 120-150m was reiterated, as the company expects sales to further grow in the coming quarters considering that i) Q1 enrollment w

Bryan, Garnier & Co Healthcare Daily | Calliditas, SVB, NK-therapies d...

Phase 3 meets eGFR primary endpoint and suggests best-case scenario

The phase 3 NefIgArd trial with Nefecon (Tarpeyo/Kinpeygo) met the primary endpoint of a two-year benefit on eGFR vs. placebo. We expect to see more details in the call later today, but Calliditas already stated that the benefit was observed irrespective of UPCR (proteinuria) at baseline. We believ